Literature DB >> 22864604

Susceptibility screening of hyphae-forming fungi with a new, easy, and fast inoculum preparation method.

Arno Schmalreck1, Birgit Willinger, Viktor Czaika, Wolfgang Fegeler, Karsten Becker, Gerhard Blum, Cornelia Lass-Flörl.   

Abstract

In vitro susceptibility testing of clinically important fungi becomes more and more essential due to the rising number of fungal infections in patients with impaired immune system. Existing standardized microbroth dilution methods for in vitro testing of molds (CLSI, EUCAST) are not intended for routine testing. These methods are very time-consuming and dependent on sporulating of hyphomycetes. In this multicentre study, a new (independent of sporulation) inoculum preparation method (containing a mixture of vegetative cells, hyphae, and conidia) was evaluated. Minimal inhibitory concentrations (MIC) of amphotericin B, posaconazole, and voriconazole of 180 molds were determined with two different culture media (YST and RPMI 1640) according to the DIN (Deutsches Institut für Normung) microdilution assay. 24 and 48 h MIC of quality control strains, tested per each test run, prepared with the new inoculum method were in the range of DIN. YST and RPMI 1640 media showed similar MIC distributions for all molds tested. MIC readings at 48 versus 24 h yield 1 log(2) higher MIC values and more than 90 % of the MICs read at 24 and 48 h were within ± 2 log(2) dilution. MIC end point reading (log(2 MIC-RPMI 1640)-log(2 MIC-YST)) of both media demonstrated a tendency to slightly lower MICs with RPMI 1640 medium. This study reports the results of a new, time-saving, and easy-to-perform method for inoculum preparation for routine susceptibility testing that can be applied for all types of spore-/non-spore and hyphae-forming fungi.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22864604     DOI: 10.1007/s11046-012-9570-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  39 in total

1.  A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592).

Authors:  E K Manavathu; J L Cutright; D Loebenberg; P H Chandrasekar
Journal:  J Antimicrob Chemother       Date:  2000-08       Impact factor: 5.790

2.  Multidrug resistance in Aspergillus fumigatus.

Authors:  Adilia Warris; Corry M Weemaes; Paul E Verweij
Journal:  N Engl J Med       Date:  2002-12-26       Impact factor: 91.245

Review 3.  The changing face of invasive fungal infections in hematopoietic cell transplant recipients.

Authors:  John R Wingard
Journal:  Curr Opin Oncol       Date:  2005-03       Impact factor: 3.645

4.  A Ser678Pro substitution in Fks1p confers resistance to echinocandin drugs in Aspergillus fumigatus.

Authors:  Eleusa Maria F Rocha; Guillermo Garcia-Effron; Steven Park; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

Review 5.  The current role of the reference procedures by CLSI and EUCAST in the detection of resistance to antifungal agents in vitro.

Authors:  Manuel Cuenca-Estrella; Juan Luis Rodriguez-Tudela
Journal:  Expert Rev Anti Infect Ther       Date:  2010-03       Impact factor: 5.091

6.  Wild-type minimum effective concentration distributions and epidemiologic cutoff values for caspofungin and Aspergillus spp. as determined by Clinical and Laboratory Standards Institute broth microdilution methods.

Authors:  Michael A Pfaller; Linda Boyken; Richard J Hollis; Jennifer Kroeger; Shawn A Messer; Shailesh Tendolkar; Daniel J Diekema
Journal:  Diagn Microbiol Infect Dis       Date:  2010-03-05       Impact factor: 2.803

Review 7.  Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection.

Authors:  Susan Julie Howard; Maiken Cavling Arendrup
Journal:  Med Mycol       Date:  2010-08-26       Impact factor: 4.076

8.  Multiple-azole-resistant Aspergillus fumigatus osteomyelitis in a patient with chronic granulomatous disease successfully treated with long-term oral posaconazole and surgery.

Authors:  Caspar J Hodiamont; Koert M Dolman; Ineke J M Ten Berge; Willem J G Melchers; Paul E Verweij; Dasja Pajkrt
Journal:  Med Mycol       Date:  2008-12-19       Impact factor: 4.076

9.  The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.

Authors:  J C Bowman; P Scott Hicks; M B Kurtz; H Rosen; D M Schmatz; P A Liberator; C M Douglas
Journal:  Antimicrob Agents Chemother       Date:  2002-09       Impact factor: 5.191

10.  Frequency and evolution of Azole resistance in Aspergillus fumigatus associated with treatment failure.

Authors:  Susan J Howard; Dasa Cerar; Michael J Anderson; Ahmed Albarrag; Matthew C Fisher; Alessandro C Pasqualotto; Michel Laverdiere; Maiken C Arendrup; David S Perlin; David W Denning
Journal:  Emerg Infect Dis       Date:  2009-07       Impact factor: 6.883

View more
  4 in total

1.  Evaluation of a modified EUCAST fragmented-mycelium inoculum method for in vitro susceptibility testing of dermatophytes and the activity of novel antifungal agents.

Authors:  B Risslegger; C Lass-Flörl; G Blum; M Lackner
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

2.  Comparison of Four Methods for the in vitro Susceptibility Testing of Dermatophytes.

Authors:  Anthi-Marina Markantonatou; Konstantinos Samaras; Evaggelia Zachrou; Timoleon-Achilleas Vyzantiadis
Journal:  Front Microbiol       Date:  2020-07-14       Impact factor: 5.640

3.  Phylogenetic relationships matter: antifungal susceptibility among clinically relevant yeasts.

Authors:  A F Schmalreck; M Lackner; K Becker; W Fegeler; V Czaika; H Ulmer; C Lass-Flörl
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

4.  In vitro susceptibility testing for black grain eumycetoma causative agents.

Authors:  Wendy W J van de Sande
Journal:  Trans R Soc Trop Med Hyg       Date:  2021-04-14       Impact factor: 2.184

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.